<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zeng H</submitter><funding>the First Affiliated Hospital of Yangtze University</funding><funding>Heath and Family Planning Commission of Hubei Province</funding><funding>the Joint Fund project of Yangtze University</funding><pagination>221-230</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11216246</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(6)</volume><pubmed_abstract>&lt;b>Objective:&lt;/b> This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). &lt;b>Methods:&lt;/b> PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. &lt;b>Results:&lt;/b> The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p &lt; 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0.009) and overall survival (p = 0.003); tumor PLK3-positive rate ≥50% showed a stronger correlation with them (both p = 0.001), which was validated by multivariate Cox regression analyses (both p &lt; 0.05). &lt;b>Conclusion:&lt;/b> Tumor PLK3-positive rate ≥50% relates to inc</pubmed_abstract><journal>Biomarkers in medicine</journal><pubmed_title>PLK3 is linked with higher tumor stage and unfavorable prognosis in patients with colorectal cancer.</pubmed_title><pmcid>PMC11216246</pmcid><funding_grant_id>WJ2019-22</funding_grant_id><funding_grant_id>WJ2018H203</funding_grant_id><funding_grant_id>2022DIF01</funding_grant_id><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>He H</pubmed_authors><pubmed_authors>Xiang Y</pubmed_authors><pubmed_authors>Zeng H</pubmed_authors><pubmed_authors>Tu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>PLK3 is linked with higher tumor stage and unfavorable prognosis in patients with colorectal cancer.</name><description>&lt;b>Objective:&lt;/b> This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). &lt;b>Methods:&lt;/b> PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. &lt;b>Results:&lt;/b> The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p &lt; 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0.009) and overall survival (p = 0.003); tumor PLK3-positive rate ≥50% showed a stronger correlation with them (both p = 0.001), which was validated by multivariate Cox regression analyses (both p &lt; 0.05). &lt;b>Conclusion:&lt;/b> Tumor PLK3-positive rate ≥50% relates to inc</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-06-26T03:06:26.64Z</modification><creation>2025-06-26T03:06:26.64Z</creation></dates><accession>S-EPMC11216246</accession><cross_references><pubmed>38629862</pubmed><doi>10.2217/bmm-2023-0591</doi></cross_references></HashMap>